Every 10-Q that CryoPort, Inc. (CYRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CYRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYRX filings page.
Cryoport, Inc. reported Q2 2026 total revenue of $48,971 (thousands), up from $45,454 (thousands) a year earlier, driven by Life Sciences Services of $27,969 (thousands) and Life Sciences Products of $21,002 (thousands). Gross margin was $22,824 (thousands), while loss from operations was $(10,039) (thousands).
Loss from continuing operations was $(8,255) (thousands), or $(0.20) per share, compared with $(12,014) (thousands), or $(0.28) per share, in Q2 2025. For the first six months of 2026, revenue reached $96,769 (thousands) and net loss was $(18,799) (thousands). Cash and cash equivalents were $269,267 (thousands) and short-term investments $127,426 (thousands), for total liquidity of $396,693 (thousands), versus Convertible Senior Notes principal of $186,185 (thousands) due in 2026. Prior-year results included a $120,883 (thousands) gain from the June 2025 sale of the CRYOPDP business, classified as discontinued operations.
Cryoport, Inc. reports Q1 2026 results with total revenue of $47.8 million, up from $41.0 million a year earlier, driven by both services and products. Life Sciences Services contributed $26.9 million and Life Sciences Products $20.9 million.
The company recorded a loss from operations of $9.6 million versus $7.2 million last year, and a net loss of $10.5 million compared with $12.0 million. Net loss attributable to common stockholders was $12.5 million, or $0.25 per share, including a $2.0 million paid‑in‑kind dividend on Series C preferred stock.
Cryoport classified its former CRYOPDP courier business as discontinued operations following its 2025 divestiture and booked a $1.1 million loss from discontinued operations tied to an adjustment on the disposal. The company ended the quarter with $403.6 million in cash, cash equivalents and short‑term investments and generated $3.7 million of operating cash flow, while carrying $186.2 million of 0.75% Convertible Senior Notes due in 2026.
Cryoport, Inc. filed its quarterly report, showing higher revenue and stronger margins alongside a major portfolio shift. Q3 revenue reached $44.233M, up from $38.317M, driven by gains in both Life Sciences Services ($24.258M) and Life Sciences Products ($19.975M). Gross margin improved to $21.325M, while loss from operations narrowed to $(9.932)M. Q3 net loss was $(6.943)M (basic and diluted $(0.18) per share).
Year-to-date, revenue was $130.727M vs. $115.317M last year. Results reflect the June 11 divestiture of the CRYOPDP specialty courier business to DHL for $133.0M plus repayment of $77.2M intercompany loans, recorded as discontinued operations and producing a $120.047M gain. This drove nine‑month net income of $89.945M, despite a continuing‑operations loss of $(25.448)M.
Liquidity strengthened: cash and cash equivalents were $255.811M and short‑term investments were $165.503M, totaling $421.314M. Total liabilities fell to $261.057M, stockholders’ equity rose to $513.271M, and the 2025 Convertible Senior Notes were repaid ($14.344M). Shares outstanding were 50,068,904 as of October 31, 2025.
Cryoport completed the divestiture of its CryoPDP specialty courier business to DHL for $133.0 million, which included repayment of approximately $77.2 million of intercompany loans and generated a reported $116,662 thousand gain on disposal classified as discontinued operations. Proceeds from the divested business of $210,239 thousand were reflected in investing cash flows and materially increased the Company's liquidity.
Total revenue increased to $45,454 thousand for the three months ended June 30, 2025 (up from $39,709) and to $86,494 thousand for the six months (up from $77,000). Results from continuing operations remained a loss: $(12,014) thousand for the quarter and $(18,752) thousand for the six months, while net income including discontinued operations was $105,180 thousand and $93,199 thousand, respectively. Cash and cash equivalents rose to $243,416 thousand at June 30, 2025; total assets were $773,927 thousand and total stockholders' equity was $515,391 thousand. Convertible senior notes noncurrent balance was $184,504 thousand and accumulated impairment losses related to goodwill/intangibles totaled $104,132 thousand.